# Montreux Equity Partners

> Montreux Equity Partners is a VC fund backing Health Care and Biotechnology. See 81 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 81
- Last investment: Jul 2024
- Lead investor: 15%
- Fund size: $74M
- Last fund: Aug 2015
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/3922200?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A3922200%2Cidx%3A1-1-1%2CtarId%3A1441118244172%2Ctas%3AMontreux%20Equity%20Partners%20
- Website: http://mepvc.com

Montreux Equity Partners is a private investment firm dedicated to building the leading healthcare companies of tomorrow.

## Contacts

5 contacts available for Montreux Equity Partners. Shizune tracks 5 team members at Montreux Equity Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/montreaux-equity-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 29 | 36% |
| Biotechnology | 19 | 23% |
| Medical | 15 | 19% |
| Medical Device | 13 | 16% |
| Pharmaceutical | 9 | 11% |

53 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 17% |
| Series A | 13 | 16% |
| Series C | 10 | 12% |
| Series D | 10 | 12% |
| Funding Round | 10 | 12% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 48% |
| Canada | 1 | 1% |
| Germany | 1 | 1% |
| Ireland | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Turner | Managing Director | 14 | https://shizune.co/investors/profile/daniel-k-turner |
| Jamey Thorson | Executive Assistant | 0 | https://shizune.co/investors/profile/jamey-thorson |
| Megan Harris | Office Manager | 0 | https://shizune.co/investors/profile/megan-harris |
| Michael Mayer | Managing Director | 0 | https://shizune.co/investors/profile/michael-mayer-944a |
| Tom Fremd | CFO | 0 | https://shizune.co/investors/profile/tom-fremd |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M | Series E | Jul 25, 2024 |  |
| Tebra | Tebra provide independent healthcare practices with digital tools and support to thrive in a new era of healthcare.Tebra is to unlock better healthcare for every patient by getting your independent practice the right technology and support to thrive. In an industry marked by broken, disparate parts, and overstuffed with processes, we aredeveloping a single system that can truly be the backbone of practice success. | $72M | Series B | Jul 07, 2022 |  |
| KEO World | KEO World is an innovative FinTech​ helping Buyers and Suppliers accelerate business growth through all-digital inventory financing and B2B payment solutions. Headquartered in Miami, Florida, KEO operates in the U.S., Mexico and across LATAM by way of its Global Trade program. | $20M | Venture - Series Unknown | Jun 14, 2022 |  |
| FinPay | FinPay is committed to solving the affordability crisis in healthcare by enhancing the patient financial experience through patient engagement, expanding healthcare financial literacy, advocating for cost transparency and offering affordable payment options, all while restoring consumer trust in the American healthcare system. | $15M | Series D | Mar 28, 2022 |  |
| FinPay | FinPay is committed to solving the affordability crisis in healthcare by enhancing the patient financial experience through patient engagement, expanding healthcare financial literacy, advocating for cost transparency and offering affordable payment options, all while restoring consumer trust in the American healthcare system. | $5M | Series C | Nov 12, 2020 |  |
| TigerConnect | TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems.Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California. | $45M | Series D | Oct 08, 2020 |  |
| Pulmonx | Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), theChartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date. | $65M | Series G | May 09, 2019 |  |
| Crown Laboratories | Crown Laboratories, Inc. is a fully integrated specialty pharmaceutical company offering Consumer Healthcare Products, Prescription Products, and Contract Development and Manufacturing Services. |  | Private Equity | May 03, 2019 |  |
| GC Aesthetics | GC Aesthetics supports surgeons and patients with our pre-surgery, surgery and post-surgery products. | $97M |  | Oct 30, 2018 |  |
| Sonoma Pharmaceuticals | Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medicalneeds of these markets—while raising the standard of patient care and lowering overall healthcare costs. | $4.6M | Post-IPO Equity | Mar 06, 2018 |  |

10 of 81 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 20 deals together
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund, 9 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 8 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 5 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Montreux Equity Partners invest in?

Montreux Equity Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 81 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Montreux Equity Partners?

Public channels for Montreux Equity Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Montreux Equity Partners?

The team at Montreux Equity Partners includes Daniel Turner (Managing Director), Jamey Thorson (Executive Assistant) and Megan Harris (Office Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co